Skip to main content
. 2021 Jun 28;14(7):624. doi: 10.3390/ph14070624

Figure 2.

Figure 2

Binding of the trastuzumab-DNA mimic conjugate to breast (MCF-7, T-47D, SK-BR-3) and ovarian (SK-OV-3) cancer cells expressing various levels of HER2 was evaluated by FACS. Cells were incubated with 10 µg/mL of the trastuzumab-DNA mimic conjugate (ADC), trastuzumab (TZ) or the irrelevant 13R4 antibody for 1 h. Then, cells were washed with cold PBS, trypsinized and 1 × 106 cells were analyzed by FACS. Untreated cells were used as a control.